Kutatási jelek – Signal Engine

• Primary adenoid cystic carcinoma of the breast: a clinicopathological case series — Breast cancer
• Dual‑Metal Organic Framework Nanozyme for Synergistic Photothermal‑Chemodynamic Therapy: Copper‑Molybdenum Synergism in Gastric Cancer Treatment — Gastric cancer
• Traditional Chinese Medicine in Gastric Cancer: A Narrative Review of Mechanisms, Clinical Evidence, Technical Advances, and Translational Challenges — Gastric cancer
• Pharmaceutical care in patients with gastric cancer treated with capecitabine: A randomized clinical trial. — Gastric cancer
• Characterization and functional analysis of miRNAs in Salvia miltiorrhiza-isolated exosome-like nanoparticles for gastric cancer treatment — Gastric cancer
• Novel Myelofibrosis Drug is “Versatile” for Managing Anemia — Myelofibrosis
• From cancer to Alzheimer’s: nine medical advances and trials to watch now — SCLC
• Neoadjuvant/Adjuvant Durvalumab Combo Elicits Sustained EFS in NSCLC — NSCLC
• Scientists make concerning discovery about lung cancer and microplastics — Lung cancer
• Protocol digest of a randomized controlled trial comparing transverse colectomy with extended right hemicolectomy for Stage II/III transverse colon cancer: JCOG2304 (TACTICS). — Colorectal cancer
• Innovative BATTLE Trials Pair Agents, Biomarkers in NSCLC — NSCLC
• Forcing Acute Myeloid Leukemia Cells to Run on Empty Shows Promise in Mice — Acute myeloid leukemia
• Pancreatic cancer: two new studies to improve treatment — Pancreatic cancer
• Colorectal Cancer ‑ Treatments, Trials & Research — Colorectal cancer
• Glioma — Glioblastoma
• Glioma — Glioblastoma
• NCT05800210: Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia — Acute lymphoblastic leukemia
• Role of Immune Checkpoint Inhibitors in Non‑Small Cell Lung Cancer Oncogenic Driver Mutations — NSCLC
• EGFR Inhibitors in Lung Cancer — NSCLC
• Multinucleated Giant Cells in Human Pancreatic Cancer Are a Distinct Macrophage Population Undergoing a DNA Damage Response and Associated with an Aggressive Tumor Microenvironment — Head and neck squamous cell carcinoma